Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 6:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 201 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Neovascularization Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Evaluate The Safety, Tolerability And Pk Of Pazopanib Eye Drops In Healthy Adult And Elderly Subjects.

NCT00463320
View directory record Official record
Conditions
Macular Degeneration, Age-related Macular Degeneration
Interventions
Pazopanib eye drops and Allergen Refresh Plus eye drops
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years to 55 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
2
States / cities
Fargo, North Dakota • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 18, 2012 · Synced Jun 10, 2026, 6:48 PM EDT
Terminated No phase listed Observational

Ultrasound and Other Images of Artery Blockages

NCT01419574
View directory record Official record
Conditions
Atherosclerosis
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
21 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 2, 2019 · Synced Jun 10, 2026, 6:48 PM EDT
Completed Phase 4 Interventional Results available

EAGLE: Evaluating Genotypes Using Intravitreal Aflibercept Injection

NCT02689518
View directory record Official record
Conditions
Macular Degeneration, Wet Macular Degeneration
Interventions
Intravitreal aflibercept injection
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
50 Years to 90 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Mar 24, 2021 · Synced Jun 10, 2026, 6:48 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pilot Study for the Treatment of Iris Neovascularization With Macugen

NCT00295828
View directory record Official record
Conditions
Iris Neovascularization, Diabetic Retinopathy
Interventions
Pegaptanib Sodium Injection/Panretinal Photocoagulation, Panretinal Photocoagulation (PRP)
Other · Procedure
Lead sponsor
Hermann Eye Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 3, 2008 · Synced Jun 10, 2026, 6:48 PM EDT
Completed Phase 1 Interventional

A Phase 1 Study of S-3304 in Patients With Solid Tumors

NCT00033215
View directory record Official record
Conditions
Solid Tumors
Interventions
S-3304
Drug
Lead sponsor
Shionogi
Industry
Eligibility
18 Years to 85 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
4
States / cities
Denver, Colorado • Tampa, Florida • Buffalo, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2018 · Synced Jun 10, 2026, 6:48 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Clinical Assessment Of Age-related Macular Degeneration Patients After Early Diagnosis and Treatment With Ranibizumab

NCT01402544
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
ranibizumab
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
50 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
4
States / cities
Bakersfield, California • La Jolla, California • Santa Barbara, California + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced Jun 10, 2026, 6:48 PM EDT
Completed Phase 4 Interventional

Comparing Post-intravitreal Injection Pain Scores Using Loteprednol, Bromfenac Sodium, and Artificial Tears Over a 24-hour Period

NCT07090044
View directory record Official record
Conditions
Vein Occlusion, Macular Degeneration Choroidal Neovascularization, Macular Edema, Diabetic Retinopathy
Interventions
Bromfenac Sodium 0.07%, Loteprednol Etabonate 0.38% Ophthalmic Gel/Jelly, Propylene Glycol Preservative-free Artificial Tears
Drug
Lead sponsor
Retina Research Institute, LLC
Other
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Jun 10, 2026, 6:48 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Short-term Clinical Effects of Intravitreal Aflibercept Injection 2.0mg as a Predictor of Long-term Results

NCT01657669
View directory record Official record
Conditions
Age Related Macular Degeneration
Interventions
Intravitreal Aflibercept injection
Drug
Lead sponsor
Retina Research Institute, LLC
Other
Eligibility
50 Years and older
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
3
States / cities
St Louis, Missouri • McAllen, Texas
Source: ClinicalTrials.gov public record
Updated Oct 26, 2017 · Synced Jun 10, 2026, 6:48 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Age-related Macular Degeneration Treatments Trials: Lucentis-Avastin Trial

NCT00593450
View directory record Official record
Conditions
Age Related Macular Degeneration
Interventions
ranibizumab, bevacizumab
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
50 Years and older
Enrollment
1,208 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
59
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2017 · Synced Jun 10, 2026, 6:48 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of RTH258 Versus Aflibercept - Study 1

NCT02307682
View directory record Official record
Conditions
Neovascular Age-Related Macular Degeneration, Choroidal Neovascularization
Interventions
Brolucizumab ophthalmic solution, Aflibercept ophthalmic solution
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
50 Years and older
Enrollment
1,775 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Jun 10, 2026, 6:48 PM EDT
Completed Phase 2 Interventional Results available

Bevacizumab in Combination With Visudyne Photodynamic Therapy (PDT)

NCT00729846
View directory record Official record
Conditions
Age Related Macular Degeneration, Choroidal Neovascularization, Macular Edema
Interventions
Bevacizumab, verteporfin photodynamic therapy reduced fluence, verteporfin photodynamic therapy standardfluence
Drug · Device
Lead sponsor
California Retina Consultants
Other
Eligibility
50 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
2
States / cities
Bakersfield, California • Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Apr 19, 2016 · Synced Jun 10, 2026, 6:48 PM EDT
Completed Phase 1 Interventional

Fluocinolone Implant to Treat Macular Degeneration

NCT00008515
View directory record Official record
Conditions
Choroidal Neovascularization, Macular Degeneration
Interventions
Fluocinolone
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jun 10, 2026, 6:48 PM EDT
Completed Not applicable Interventional

A 16 Week Evaluation of the Novartis Health Management Tool (HMT) in Age Related Macular Degeneration (AMD)

NCT01542866
View directory record Official record
Conditions
Age Related Macular Degeneration (AMD)
Interventions
Health Management Tool (HMT)
Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
Not listed
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
23
States / cities
Beverly Hills, California • Sacramento, California • Torrance, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2018 · Synced Jun 10, 2026, 6:48 PM EDT
Not listed Not applicable Interventional

Episcleral Brachytherapy for the Treatment of Wet AMD

NCT02988895
View directory record Official record
Conditions
Macular Degeneration, Choroidal Neovascularization
Interventions
episcleral brachytherapy
Radiation
Lead sponsor
Salutaris Medical Devices, Inc.
Industry
Eligibility
50 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
2
States / cities
‘Aiea, Hawaii • Oak Forest, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 29, 2023 · Synced Jun 10, 2026, 6:48 PM EDT
Completed No phase listed Observational

Testing the Effectiveness of the Interactive Tutorial of the Home Macular Perimeter (HMP)

NCT00603850
View directory record Official record
Conditions
Age Related Macular Degeneration
Interventions
ForeseeHome
Device
Lead sponsor
Notal Vision Ltd.
Industry
Eligibility
50 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 13, 2015 · Synced Jun 10, 2026, 6:48 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (TENAYA)

NCT03823287
View directory record Official record
Conditions
Wet Macular Degeneration
Interventions
Faricimab, Aflibercept, Sham Procedure
Drug · Procedure
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years and older
Enrollment
671 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
52
States / cities
Phoenix, Arizona • Tucson, Arizona • Campbell, California + 47 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2025 · Synced Jun 10, 2026, 6:48 PM EDT
Completed Not applicable Interventional Results available

Proposal for Intraoperative Administration of Intravenous Indocyanine Green to Evaluate Position of the Optic Canal, Position of the Internal Carotid Arteries, Tumor Vascularization, and Vessel Encasement in Endoscopic Endonasal Cranial Base Surgery

NCT03072186
View directory record Official record
Conditions
Skull Base Neoplasms, Skull Neoplasms, Bone Neoplasm, Neoplasms, Bone Diseases, Musculoskeletal Disease
Interventions
near-infrared light nasal endoscope used with ICG
Device
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 25, 2021 · Synced Jun 10, 2026, 6:48 PM EDT
Recruiting Phase 2Phase 3 Interventional

Corneal Crosslinking for Treatment of Corneal Neovascularization

NCT04787471
View directory record Official record
Conditions
Corneal Neovascularization
Interventions
30 minute photoactivation of riboflavin 0.1%, 10 minute photoactivation of riboflavin 0.1%
Combination Product
Lead sponsor
Price Vision Group
Industry
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Jun 10, 2026, 6:48 PM EDT
Recruiting No phase listed Observational

Perfusion MRI-targeted Joint Embolization for Chronic Musculoskeletal Pain of the Shoulder, Hip and Knee

NCT05700682
View directory record Official record
Conditions
Osteoarthritis, Knee, Osteoarthritis, Hip, Osteo Arthritis Shoulders, Synovitis of Knee, Synovitis/Tenosynovitis - Hip, Synovitis, Pain, Chronic
Interventions
Shoulder/Hip/Knee Embolization with Embozene Microspheres
Device
Lead sponsor
Palo Alto Veterans Institute for Research
Other
Eligibility
25 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Jun 10, 2026, 6:48 PM EDT
Completed Phase 3 Interventional

Triamcinolone Acetonide Plus Laser Therapy to Treat Age-Related Macular Degeneration

NCT00100009
View directory record Official record
Conditions
Macular Degeneration
Interventions
TAC-PF, Triamcinolone Acetonide
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
50 Years to 100 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
23
States / cities
Tucson, Arizona • Los Angeles, California • Miami, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jun 10, 2026, 6:48 PM EDT
Completed Phase 3 Interventional

An Evaluation of Safety and Efficacy of Anecortave Acetate Versus Placebo in Patients With Subfoveal CNV Due to Exudative AMD

NCT00058994
View directory record Official record
Conditions
Macular Degeneration, Maculopathy, Age-Related
Interventions
anecortave acetate
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
50 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Nov 28, 2012 · Synced Jun 10, 2026, 6:48 PM EDT
Completed No phase listed Observational

Sensitivity of the Home Macular Perimeter (HMP)

NCT00604071
View directory record Official record
Conditions
Age Related Macular Degeneration, Choroidal Neovascularization
Interventions
Not listed
Lead sponsor
Notal Vision Ltd.
Industry
Eligibility
50 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
10
States / cities
Lakeland, Florida • Palm Beach Gardens, Florida • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2015 · Synced Jun 10, 2026, 6:48 PM EDT
Completed Phase 1 Interventional

CAPTAIN:Choroidal Neovascularization Assessment by Pattern Electroretinography

NCT00500344
View directory record Official record
Conditions
Age-related Macular Degeneration
Interventions
Lucentis (ranibizumab)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
50 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 2, 2018 · Synced Jun 10, 2026, 6:48 PM EDT
Completed Not applicable Interventional

Randomized Study of Photodynamic Therapy Using Dihematoporphyrin in Patients With Corneal Neovascularization

NCT00004430
View directory record Official record
Conditions
Corneal Neovascularization
Interventions
Dihematoporphyrin derivative, prednisolone, Laser surgery
Drug · Procedure
Lead sponsor
Medical College of Hampton Roads
Other
Eligibility
12 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 1998
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 24, 2015 · Synced Jun 10, 2026, 6:48 PM EDT